Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Energy supply–demand matching in health and heart failure

Published byRandolph Garrett Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Energy supply–demand matching in health and heart failure"— Presentation transcript:

1 Figure 1 Energy supply–demand matching in health and heart failure
Figure 1 | Energy supply–demand matching in health and heart failure. The delicate balance between cardiac demands for energy and supply of energy is tipped in heart failure, in which energy supply cannot match demand. Next-generation therapeutics can improve on existing standard-of-care therapies by bolstering mitochondrial energy production. ACE, angiotensin-converting enzyme; ARB, angiotensin II-receptor blocker; ETC, electron transport chain; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ROS, reactive oxygen species. Brown, D. A. et al. (2016) Mitochondrial function as a therapeutic target in heart failure Nat. Rev. Cardiol. doi: /nrcardio

Download ppt "Figure 1 Energy supply–demand matching in health and heart failure"

Similar presentations

Fig ACCF/AHA Guideline for the management of heart failure

Fig ACCF/AHA Guideline for the management of heart failure
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),
Figure 1 Mechanisms of action of novel therapeutics for heart failure

Figure 1 Mechanisms of action of novel therapeutics for heart failure
by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B
Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.
Figure 2 Muscle structure

Figure 2 Muscle structure
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Metabolism in homeostatic chondrocytes

Figure 3 Metabolism in homeostatic chondrocytes
Reproduced with permission from Yancy, C. W. et al. 2017

Reproduced with permission from Yancy, C. W. et al. 2017
Figure 2 Risk factors for sarcopenia

Figure 2 Risk factors for sarcopenia
Figure 8 Implanted devices for the management of heart failure

Figure 8 Implanted devices for the management of heart failure
Figure 4 Autophagy and ischaemia–reperfusion

Figure 4 Autophagy and ischaemia–reperfusion
Diabetes Mellitus and Heart Failure

Diabetes Mellitus and Heart Failure
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Clyde W. Yancy et al. JACC 2017;70:

Clyde W. Yancy et al. JACC 2017;70:
Figure 1 Signalling pathways involved in muscle wasting in heart failure Figure 1 | Signalling pathways involved in muscle wasting in heart failure. Pathways.

Figure 1 Signalling pathways involved in muscle wasting in heart failure Figure 1 | Signalling pathways involved in muscle wasting in heart failure. Pathways.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 7 European Society of Cardiology 2016

Figure 7 European Society of Cardiology 2016

Similar presentations

Ads by Google